Table 2 Clinical characteristics of the 7 patients diagnosed with cyclosporine A-related neurotoxicity
Patient number | #1 | #2 | #3 | #4 | #5 | #6 | #7 |
|---|---|---|---|---|---|---|---|
Gender | M | F | M | M | F | M | M |
Age at HID-HSCT (years) | 8 | 7 | 7 | 9 | 8 | 7 | 4 |
Underlying disease | MDS | ALL | AML | MDS-SAML | AML | AML | ALL |
Remission status | NR | CR1 | CR1 | CR1 | CR1 | CR1 | PR |
HLA typing | 6/10 | 5/10 | 7/10 | 5/10 | 5/10 | 5/10 | 5/10 |
Donor-recipient gender | F-M | F-F | F-M | F-M | M-F | M-M | M-M |
ABO type of donor and recipient | Matched | Mismatched | Mismatched | Mismatched | Matched | Mismatched | Matched |
Mononuclear cells (× 108/kg) | 6.14 | 13.1 | 17.5 | 17.45 | 5.6 | 1.82 | 16.37 |
CD34+ cells (×106/kg) | 2.3 | 2.5 | 6.85 | 3.17 | 8.81 | 10.14 | 5.33 |
Neutrophil engraftment time (days) | 11 | 10 | 11 | 19 | 12 | 16 | 10 |
Thrombocyte engraftment time (days) | 15 | 10 | 11 | 22 | 12 | 17 | 10 |